Exquiron Biotech
Recherche et développement pharmaceutiques is dedicated to guiding companies through the drug discovery and development process, focusing on creating effective pharmaceutical products that meet clinical trial standards. They emphasize a dossier-centered approach to accelerate product compliance and possess expertise in solid state research, bioavailability improvement, and modified release. Their mission includes advancing cancer and infectious disease treatments, leveraging innovative technologies, and fostering collaboration to bring new medicines from laboratory to patient care.
Industries
Nr. of Employees
small (1-50)
Services
Design, planning and execution support for Phase I–III oncology clinical studies, including data capture and analysis to detect early efficacy signals.
Preclinical study design and execution using a broad panel of cancer models and virology-focused discovery workflows to advance compounds to IND-enabling studies.
Assessment of regulatory readiness, preparation of IND filings and management of regulatory interactions to facilitate clinical entry.
Pharmacokinetic and drug metabolism studies and analyses to support candidate selection and program strategy.
Lead optimization, chemical synthesis and organization of compound collections to enable biological screening and progression toward preclinical candidates.
Development and application of biomarkers and translational strategies to connect preclinical findings with clinical endpoints.
Design, planning and execution support for Phase I–III oncology clinical studies, including data capture and analysis to detect early efficacy signals.
Preclinical study design and execution using a broad panel of cancer models and virology-focused discovery workflows to advance compounds to IND-enabling studies.
Assessment of regulatory readiness, preparation of IND filings and management of regulatory interactions to facilitate clinical entry.
Pharmacokinetic and drug metabolism studies and analyses to support candidate selection and program strategy.
Lead optimization, chemical synthesis and organization of compound collections to enable biological screening and progression toward preclinical candidates.
Development and application of biomarkers and translational strategies to connect preclinical findings with clinical endpoints.
Expertise Areas
- Oncology drug discovery
- Clinical trial management (Phase I–III)
- Preclinical in vivo pharmacology
- DMPK / PK / ADME
Key Technologies
- High-throughput screening (HTS)
- In vivo tumor models (large panel)
- Induced pluripotent stem cell (iPSC) models
- Bioinformatics and human genome data analysis